Zhongyu Zhu, Ph.D.
Staff Scientist

Dr. Zhu's research interests focus on antibody-based therapeutics development through phage and yeast display antibody library technology. Specifically, Dr. Zhu is interested in the following 3 categories. 1) Naked Antibody: Full-size antibody can serve as a modulator of disease-causing protein-protein interactions and mediator of immune responses toward disease targets for drug development. 2) Antibody-Drug Conjugates (ADCs): ADCs provide biomarker-targeted delivery of a toxic drug for cancer therapy. 3) Chimeric Antigen Receptors (CARs): Engineered antibody fragment can be expressed as CARs on T cells for cancer biomarker-targeted T-cell-based immunotherapy.

Areas of Expertise
1) antibody-based therapeutics

Contact Info

Zhongyu Zhu, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 567, Room 180
Frederick, MD 21702-1201
301-846-5809
zhuzhongyu@mail.nih.gov

Antibodies are a key component of the immune system, playing a central role in antigen/pathogen recognition and stimulation of immune response, and also functioning as a huge collection of naturally produced medicine targeting various diseases. Our research interests focus on antibody-based therapeutics development through phage and yeast display antibody library technology. Working together with our collaborators, we are particularly interested in the following three categories: 1) Naked Antibody: Full-size antibody can serve as a modulator of disease-causing protein-protein interactions and mediator of immune responses toward disease targets for drug development. 2) Antibody-Drug Conjugates (ADCs): ADCs provide biomarker-targeted delivery of toxic drug for cancer therapy. 3) Chimeric Antigen Receptors (CARs): Engineered antibody fragment can be expressed as CARs on T cells for cancer biomarker-targeted T cell-based immunotherapy.

Selected Publications
  1. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD.
    J Virol. 88: 2426-41, 2014. [ Journal Article ]
  2. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS.
    J Virol. 88: 1125-39, 2014. [ Journal Article ]
  3. Xu K, Rockx B, Xie Y, DeBuysscher BL, Fusco DL, Zhu Z, Chan YP, Xu Y, Luu T, Cer RZ, Feldmann H, Mokashi V, Dimitrov DS, Bishop-Lilly KA, Broder CC, Nikolov DB.
    PLoS Pathog. 9: e1003684, 2013. [ Journal Article ]
  4. Chen W, Feng Y, Zhao Q, Zhu Z, Dimitrov DS.
    Mol Cancer Ther. 11: 1400-10, 2012. [ Journal Article ]
  5. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B.
    Sci Transl Med. 3: 105ra103, 2011. [ Journal Article ]

Dr. Zhongyu Zhu obtained his Ph.D. from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences. He came to the NCI for his postdoctoral research training and then became a staff scientist in Dr. Dimiter Dimitrov's group in the CCR Nanobiology Program. Currently, Dr. Zhu is with the Laboratory of Experimental Immunology, Cancer and Inflammation Program. Dr. Zhu's research interests focus on therapeutic antibody development through antibody engineering.

Research

Antibodies are a key component of the immune system, playing a central role in antigen/pathogen recognition and stimulation of immune response, and also functioning as a huge collection of naturally produced medicine targeting various diseases. Our research interests focus on antibody-based therapeutics development through phage and yeast display antibody library technology. Working together with our collaborators, we are particularly interested in the following three categories: 1) Naked Antibody: Full-size antibody can serve as a modulator of disease-causing protein-protein interactions and mediator of immune responses toward disease targets for drug development. 2) Antibody-Drug Conjugates (ADCs): ADCs provide biomarker-targeted delivery of toxic drug for cancer therapy. 3) Chimeric Antigen Receptors (CARs): Engineered antibody fragment can be expressed as CARs on T cells for cancer biomarker-targeted T cell-based immunotherapy.

Publications

Selected Publications
  1. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD.
    J Virol. 88: 2426-41, 2014. [ Journal Article ]
  2. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS.
    J Virol. 88: 1125-39, 2014. [ Journal Article ]
  3. Xu K, Rockx B, Xie Y, DeBuysscher BL, Fusco DL, Zhu Z, Chan YP, Xu Y, Luu T, Cer RZ, Feldmann H, Mokashi V, Dimitrov DS, Bishop-Lilly KA, Broder CC, Nikolov DB.
    PLoS Pathog. 9: e1003684, 2013. [ Journal Article ]
  4. Chen W, Feng Y, Zhao Q, Zhu Z, Dimitrov DS.
    Mol Cancer Ther. 11: 1400-10, 2012. [ Journal Article ]
  5. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B.
    Sci Transl Med. 3: 105ra103, 2011. [ Journal Article ]

Biography

Dr. Zhongyu Zhu obtained his Ph.D. from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences. He came to the NCI for his postdoctoral research training and then became a staff scientist in Dr. Dimiter Dimitrov's group in the CCR Nanobiology Program. Currently, Dr. Zhu is with the Laboratory of Experimental Immunology, Cancer and Inflammation Program. Dr. Zhu's research interests focus on therapeutic antibody development through antibody engineering.